問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result > Study Site

Study Site



Taichung Veterans General Hospital

Link to Hospital

  • 1,624

    Total Beds

  • 934

    Total Doctors

  • tcvghcrc@vghtc.gov.tw
  • Clinical Research Center
  • 04-23592525#4780
  • 407Taichung CityTaichung Xitun1650 Taiwan Boulevard Sect. 4, Taichung, Taiwan 407219, ROC

Recruiting Trial

640Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

1449Cases

2013-02-07 - 2020-03-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2016-07-28 - 2020-11-01

Phase III

A Phase 3, Multicenter, Multinational, Randomized, Open-Label, Parallel-Arm Study of Avelumab (MSB0010718C) Plus Best Supportive Care Versus Best Supportive Care Alone as a Maintenance Treatment in Patients with Locally Advanced or Metastatic Urothelial Cancer Whose Disease Did Not Progress After Completion of First-Line Platinum-Containing Chemotherapy

  • Condition/Disease

    Locally Advanced or Metastatic Urothelial Cancer

  • Test Drug

    Avelumab (MSB0010718C)

Participate Sites
6Sites

Terminated6Sites

2016-07-05 - 2020-07-05

Phase II

ONO-4538 Phase II/III Study Multicenter, Open-Label, Randomized Study in Patients with Unresectable Advanced or Recurrent Gastric Cancer

  • Condition/Disease

    Advanced or Recurrent Gastric Cancer

  • Test Drug

    Nivolumab

Participate Sites
12Sites

Terminated10Sites

陳仁熙
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

白禮源
China Medical University Hospital-Taipei

未分科

2016-08-01 - 2024-12-31

Phase III

A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

  • Condition/Disease

    Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

  • Test Drug

    Xtandi® Soft Capsules 40 mg

Participate Sites
6Sites

Terminated5Sites

馮思中
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

黃書彬
Kaohsiung Municipal Gangshan Hospital

未分科

2016-09-01 - 2018-11-30

Others

A Phase 1/2, Randomized, Single-Blind, Placebo-Controlled, Single-Ascending and Multiple-Ascending Dose, Safety, Tolerability, Pharmacokinetics, and Antiviral Efficacy Study of Subcutaneously Administered ALN-HBV in Healthy Adult Subjects and Non-cirrhotic Patients with Chronic Hepatitis B Virus (HBV) Infection

  • Condition/Disease

    Chronic Hepatitis B Virus (HBV) Infection

  • Test Drug

    ALN-HBV

Participate Sites
6Sites

Terminated5Sites

2015-08-01 - 2020-03-31

Phase III

A Phase 3 Open-Label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation

  • Condition/Disease

    Acute Myeloid Leukemia (AML)

  • Test Drug

    ASP2215 Down-sized Tablets 40 mg

Participate Sites
9Sites

Terminated8Sites

2015-09-01 - 2018-07-31

Phase II

A Phase II Multicenter, Randomized, Double-blind, Placebo controlled, Dose-range Finding Study to Evaluate the Safety and Efficacy of ALX 0061 Administered Subcutaneously in Subjects with Moderate to Severe Active Systemic Lupus Erythematosus

  • Condition/Disease

    Systemic Lupus Erythematosus (SLE)

  • Test Drug

    ALX-0061

Participate Sites
7Sites

Terminated5Sites

黃春明
China Medical University Hospital-Taipei

未分科

2014-11-01 - 2022-02-28

Phase III

A Phase 3, Multicenter, Open-label, Randomized Study of nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects With Surgically Resected Pancreatic Adenocarcinoma

  • Condition/Disease

    Pancreatic Adenocarcinoma

  • Test Drug

    nab-Paclitaxel

Participate Sites
6Sites

Terminated6Sites

2014-12-01 - 2017-09-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2015-02-01 - 2016-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

1 100 101 102 103 104 145
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB